Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05200286 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment
A Phase 1 study, sponsored by F2G Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT05200286 is a Phase 1 study that has completed, run by F2G Biotech. The registered enrollment target is 16 participants.
The verdict
NCT05200286, a Phase 1 study, has completed, sponsored by F2G Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
A single oral dose study to investigate the PK and safety of olorofim in subjects with severe renal impairment compared to subjects with normal renal function.
Interventions
- DRUG Olorofim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2022-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05200286
The ClinicalTrials.gov registry entry for NCT05200286 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is F2G Biotech, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Olorofim is the first listed.
NCT05200286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05200286 about?
NCT05200286 is a clinical study titled "A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment". A single oral dose study to investigate the PK and safety of olorofim in subjects with severe renal impairment compared to subjects with normal renal function.
What is the current status of trial NCT05200286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2022-02-10. Estimated completion is 2022-12-13.
What interventions are being tested in trial NCT05200286?
The interventions under investigation include: Olorofim (DRUG).
Who is sponsoring clinical trial NCT05200286?
This trial is sponsored by F2G Biotech, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.